搜尋
Bicycle Therapeutics PLC
BCYC添加自選
3.735USD
+0.105+2.89%
交易中 09/22, 12:26（美東）
188.16M總市值
虧損本益比TTM
關於 {index_name} Bicycle Therapeutics PLC 公司
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics PLC 簡介
公司代碼BCYC
公司名稱Bicycle Therapeutics PLC
上市日期May 23, 2019
CEOLee (Kevin)
員工數量305
證券類型Depository Receipt
年結日May 23
公司地址Blocks A & B, Portway Building
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United Kingdom
郵編CB21 6GS
電話11441223261503
網址https://www.bicycletherapeutics.com/
公司代碼BCYC
上市日期May 23, 2019
CEOLee (Kevin)
Bicycle Therapeutics PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Corporate Development Officer
Chief Corporate Development Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
758.00
-300.00%
Sir Gregory Winter
Sir Gregory Winter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alethia R. Young, M.D.
Ms. Alethia R. Young, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Corporate Development Officer
Chief Corporate Development Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
常見問題
Bicycle Therapeutics PLC的前五大股東是誰？
Bicycle Therapeutics PLC的前五大股東如下：Dr. Kevin Lee, Ph.D.
有多少機構持有Bicycle Therapeutics PLC(BCYC)的股份？
截至2026Q1，共有250家機構持有Bicycle Therapeutics PLC的股份，合計持有的股份價值約為33.87M，占公司總股份的67.23% 。與2025Q4相比，機構持股有所增加，增幅為-23140757.00。